Author: ksb220805@gmail.com

[IR] Samsung Electronics (005930) – Q2 2026 Earnings Presentation / 2026-07-30

July 30, 2026August 23, 2026 ksb220805@gmail.com

💡 3-Second Summary Driven by strong AI server semiconductor demand, Samsung Electronics posted consolidated revenue of KRW 171.5T and operating profit of KRW 89.5T in Q2 2026. For H2 2026, the company plans to expand HBM4 supply and begin mass production of 2nm 2nd-generation mobile chips, while the DX division focuses on cost optimization and…

IR Room

[Research] Hanwha Ocean (042660) – Daishin | Merchant Vessel Margin · FX Impact · US Navy Logistics Synergy / 2026-07-29

July 29, 2026August 22, 2026 ksb220805@gmail.com

Brokerage : Daishin Securities Analyst : Jini Lee Investment Rating : BUY (Maintained) Target Price : KRW 139,000 (Maintained) Core Momentum : Surging merchant vessel profitability driven by a higher share of high-margin LNGC vintage recognition and favorable FX effects, coupled with emerging execution synergies with Philly Shipyard for US naval auxiliary programs 📊 1….

Research, Shipbuilding

[Research] SK hynix (000660 / SKHY) – DS Investment | Commodity DRAM · ASP Resilience · Earnings Growth / 2026-07-29

July 29, 2026August 24, 2026 ksb220805@gmail.com

Brokerage : DS Investment & Securities Market: KOSPI (000660) Analyst : Surim Lee Investment Rating : BUY (Maintain) Target Price : KRW 3,100,000 (Maintain) Core Momentum : A higher commodity DRAM production mix is expected to sustain resilient ASPs in the second half, supporting sequential quarterly operating profit growth through 4Q27 amid an absence of…

Research, Semiconductors

[Research] SK hynix (000660 / SKHY) – Mirae Asset | ROE Expansion · Net Cash · Shareholder Returns / 2026-07-29

July 29, 2026August 24, 2026 ksb220805@gmail.com

Market: KOSPI (000660) Brokerage : Mirae Asset Securities Analyst : Younggun Kim Investment Rating : BUY (Maintain) Target Price : KRW 2,800,000 (Lowered) Core Momentum : Sustained memory pricing strength and AI infrastructure demand are expected to support structurally higher ROE, while substantial net cash accumulation creates significant capacity for shareholder returns and reinforces valuation…

Research, Semiconductors

[IR] SK hynix (000660 / SKHY) – Q2 2026 Earnings Presentation / 2026-07-29

July 29, 2026August 23, 2026 ksb220805@gmail.com

Market: KOSPI (000660) 💡 3-Second Summary SK hynix reported Q2 2026 revenue of KRW 79.32T and an operating profit of KRW 60.54T (76% OPM), while initiating HBM4 volume shipments in Q2, expanding 321-layer NAND capacity, and pulling in the M15X ramp-up timeline to capture expanding Agentic AI memory demand. 📊 1. [Key Guidance & Quantitative…

IR Room

[Research] Celltrion (068270) – iM Securities | New Product Mix Expansion · First-Mover Advantage · Two-Track Long-Term Strategy / 2026-07-28

July 28, 2026August 23, 2026 ksb220805@gmail.com

Brokerage : iM Securities Analyst : Jae-won Jeong Investment Rating : Buy (Maintained) Target Price : KRW 260,000 (Maintained) Core Momentum : Quality of earnings improving through the expanding sales mix of lower-cost-ratio new products and long-term execution of the two-track biosimilar and novel drug strategy 📊 1. [Valuation & Key Financial Metrics] 🚀 2….

Research, Bio & Healthcare

[Research] Celltrion (068270) – Shinhan Securities | North American New Product Penetration · 2030 Pipeline · New Drug Cycle / 2026-07-28

July 28, 2026August 23, 2026 ksb220805@gmail.com

Brokerage : Shinhan Securities Analyst : Ho-chul Lee, Min-yong Eom Investment Rating : BUY (Maintained) Target Price : KRW 290,000 (Raised) Core Momentum : Entering a virtuous cycle where expanding North American new product sales and a 2030 portfolio of 18 biosimilars support proprietary new drug development 📊 1. [Valuation & Key Financial Metrics] 🚀…

Research, Bio & Healthcare

[Research] Celltrion (068270) – Mirae Asset Securities | New Product Mix Expansion · In-House Cost Efficiency · Valuation vs Peers / 2026-07-28

July 28, 2026August 23, 2026 ksb220805@gmail.com

Brokerage : Mirae Asset Securities Analyst : Seung-min Kim Investment Rating : BUY (Maintained) Target Price : KRW 280,000 (Raised) Core Momentum : Earnings estimate upgrades driven by stronger-than-expected profitability contributions from new biosimilars and favorable valuation vs global peers supported by in-house cost efficiency 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market…

Research, Bio & Healthcare

[Research] Celltrion (068270) – Daishin Securities | New Product Mix · H2 Margin Expansion · New Drug Pipeline / 2026-07-28

July 28, 2026August 23, 2026 ksb220805@gmail.com

Brokerage : Daishin Securities Analyst : Kahye Hong Investment Rating : BUY (Maintained) Target Price : KRW 280,000 (Maintained) Core Momentum : H2 margin expansion driven by European tender shipments and new product mix, alongside upcoming clinical milestones for the new drug pipeline 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities &…

Research, Bio & Healthcare

[Research] Celltrion (068270) – Yuanta Securities | New Product Mix Expansion · Pipeline Addition · Earnings Growth / 2026-07-28

July 28, 2026August 23, 2026 ksb220805@gmail.com

Brokerage : Yuanta Securities Analyst : Hyun-soo Ha Investment Rating : BUY (Maintained) Target Price : KRW 280,000 (Raised) Core Momentum : Rapid revenue growth in new biosimilars driving profitability improvement and pipeline expansion sustaining mid-to-long-term earnings growth 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities & Business Outlook] 📝 Editor’s Comment…

Research, Bio & Healthcare